ICHRegulatory IntelligenceGuidance
ICH Q8(R2)

Pharmaceutical Development

Provides guidance on the contents of the pharmaceutical development section of a marketing application and introduces Quality by Design (QbD) concepts including Critical Quality Attributes, Critical Process Parameters, and Design Space.

LAST REVISED
August 2009
PRODUCT AREAS
SterileSolid DoseApi
SCOPE & APPLICABILITY

Drug product development across all dosage forms. Primary audience is development scientists and regulatory affairs for submission preparation. Commercial manufacturing teams implement the design space.

KEY REQUIREMENTS
  • 01Identification and justification of Critical Quality Attributes (CQAs)
  • 02Risk-based identification of Critical Process Parameters (CPPs) from QbD studies
  • 03Design space definition — multidimensional combinations of inputs within which quality is assured
  • 04Control strategy linking CQAs and CPPs to manufacturing controls
IMPLEMENTATION TIPS
CQA list should flow from development through to commercial batch release specifications
Design space approved in submission constrains what changes can be made post-approval without filing
REVISION NOTES

R2 issued August 2009 — no revisions since. Core QbD concepts remain current; FDA Process Validation (2011) built upon the Q8 foundation.

ICH Q8(R2): frequently asked questions

Quick answers to common questions about ICH Q8(R2).

What is ICH Q8(R2)?

ICH Q8(R2) — Pharmaceutical Development — is a guidance issued by the International Council for Harmonisation. Provides guidance on the contents of the pharmaceutical development section of a marketing application and introduces Quality by Design (QbD) concepts including Critical Quality Attributes, Critical Process Parameters, and Design Space.

Who does ICH Q8(R2) apply to?

Drug product development across all dosage forms. Primary audience is development scientists and regulatory affairs for submission preparation. Commercial manufacturing teams implement the design space.

What are the key requirements of ICH Q8(R2)?

ICH Q8(R2) requires, among other things: Identification and justification of Critical Quality Attributes (CQAs); Risk-based identification of Critical Process Parameters (CPPs) from QbD studies; Design space definition — multidimensional combinations of inputs within which quality is assured; Control strategy linking CQAs and CPPs to manufacturing controls.

When was ICH Q8(R2) last updated?

The current version of ICH Q8(R2) dates from August 2009. R2 issued August 2009 — no revisions since. Core QbD concepts remain current; FDA Process Validation (2011) built upon the Q8 foundation.

RELATED STANDARDS
RELATED FDA RECALLS
where Validation & Qualification control fails
See all Validation & Qualification recalls →

Live openFDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.

THIS STANDARD IN PRACTICE

Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.

Weekly Briefing

Track the standards that move

When ICH Q8(R2) — or any GxP requirement — is revised, recalled against, or clarified by new guidance, the Weekly GxP Briefing surfaces it. Free, one email a week.

Read a past issue →